Trigen, a private company with 25 staff across offices in London and Munich, specialises in cardiovascular drug discovery and development. It focuses on drugs which target thrombosis and atherosclerosis – the hardening or ‘furring’ of arteries.
In the medium term, the head of corporate comms role will be divided between Trigen finance director Barry Knight, CEO Sanjay Kakkar and a PR agency which the company refused to name. ‘We won’t need to replace him directly for the foreseeable future, we are in a quiet news period,’ said Knight.
Tapp worked for Trigen for three years. Before that he was at biotech, pharma and healthcare comms agency Noonan/Russo for five years. He joins Abchurch as an account director in the agency’s life sciences division, reporting to chief executive Julian Bosdet.